Articles

2021

Moye-Holz D, Vogler S.: Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America. Applied Health Economics and Health Policy 2021

Vogler S, Schneider P, Zuba M, Busse R, Panteli D.: Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure. Frontiers in Pharmacology 2021

Vogler S.: Can we achieve affordable cancer medicine prices? Developing a pathway for change. Expert Review of Pharmacoeconomics & Outcomes Research. 2021: 1-5

Vogler S, Zimmermann N, Babar-Ud-Din Z, Busse R, Espin Balbino J, et al.: Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference. Journal of Pharmaceutical Policy and Practice 2021; 14(18)

2020

Vogler S, Schneider P, Lepuschütz L.: Impact of changes in the methodology of external price referencing on medicine prices:discrete-event simulation. Cost Effectiveness and Resource Allocation 2020; 18(51)

Gombocz M, Vogler S.: Public spending on orphan medicines: a review of the literature. Journal of Pharmaceutical Policy and Practice 2020; 13 (66)

Vogler S, Fischer S.: How to address medicines shortages: Findings from a cross-sectional study of 24 countries. Health Policy 2020; 124(12): 1287-1296

Gamba S, Pertile P, Vogler S.: The impact of managed entry agreements on pharmaceutical prices. Health Economics 2020; 29 (S1): 47-62

Rintoul A, Colbert A, Garner S, Kotwani A, Vogler S, Bouvy J et al.: Medicines with one seller and many buyers: strategies to increase the power of the payer. BMJ 2020; 369: m1705 

Ferrario A, Dedet G, Humbert T, Vogler S, Suleman F, Bak Pedersen H.: Strategies to achieve fairer prices for generic and biosimilar medicines. BMJ 2020; 368 :l5444

2019

Vogler S, Zimmermann N, Haasis MA, Babar-Ud-Din Z, Busse R, Espin Balbino J, et al.: Can pharmaceutical pricing and reimbursement policies make a difference in promoting equitable access to affordable medicines? From diagnosis to sustainable impact. Editorial. 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies: Vienna, Austria. 23-24 October 2019. Journal of Pharmaceutical Policy and Practice. 2019;12(Suppl 1):34

Vogler S.: Il miglioramento dei processi, la cooperazione, l’evidenza e la trasparenza: i temi chiave per le proposte di riforma delle politiche sul prezzo e rimborso dei farmaci. (Title in English: Improvement of processes, cooperation, evidence and transparency: the key proposals for reforming pharmaceutical pricing and reimbursement policies) Politiche sanitarie 2019; 20(4):180-182

Vogler S, Dedet G, Bak Pedersen H.: Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries. Appl Health Econ Health Policy 17 2019; 803–816; doi:10.1007/s40258-019-00509-z

Vogler S, Schneider P, Dedet G, Bak Pedersen H. Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan. International Journal for Equity in Health. 2019;18(1):89

Vogler S.: Fair prices for medicines? Exploring competent authorities’ and public payers’ preferences on pharmaceutical policies. Empirica - Journal of European Economics 2019; 46(3), 443-469

Vogler S, Schneider P.: Assessing Data Sources for Medicine Price Studies. International Journal of Technology Assessment in Health Care 2019; 35(2): 106-115

Vogler S, Schneider P, Zimmermann N.: Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing. PharmacoEconomics - Open (2019) 3:303–309 

Mardetko N, Kos M, Vogler S.: Review of studies reporting actual prices for medicines. Expert review of pharmacoeconomics & outcomes research 2019; 19(2): 159-179

2018

Vogler S, de Rooij R.: Medication wasted – Contents and costs of medicines ending up in household garbage. Research in Social and Administrative Pharmacy, 2018, Volume 14, Issue 12, December 2018, Pages 1140-1146

2017

Gammie T, Vogler S, Babar Z-U-D.: Economic Evaluation of Hospital and Community Pharmacy Services: A Review of the Literature (2010-2015). Annals of Pharmacotherapy, 51(1): 54-65, 2017

Schneider P, Renner A, Bobek J, Vogler S, Ostermann H.: Economic Evaluation of Minor Ailment Schemes (MAS). DOI: 10.1055/s-0042-120488, Gesundheitsökonomie & Qualitätsmanagement, 2017, 22(S 01): S23-S29

Morgan S, Vogler S, Wagner A.: Payers’ experiences with confidential pharmaceutical Price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy, 121, Issue 4: 354-362, April 2017, http://dx.doi.org/10.1016/j.healthpol.2017.02.002

Pauwels K, Huys I, Vogler S, Casteels M, Simoens S.: Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. Frontiers in Pharmacology, 2017, doi: 10.3389/fphar.2017.00171

Schneider P, Vogler S, Zimmermann N.: Oberes Mittelfeld - Ergebnisse einer Preisvergleichsstudie zu kostenintensiven Arzneimitteln. (Title in English: Upper midrange - anaylsis of high priced medicines in Austria), Das österreichische Gesundheitswesen – ÖKZ, 58. Jg. (2017), 05: 15-17, 2017

Vogler S, Paterson K.: Can Price Transparency Contribute to More Affordable Patient Access to Medicines?. PharmacoEconomics Open, 1 (3): 145-147, 2017

Vogler S, Gombocz M, Zimmermann N.: Tendering for off-patent outpatient medicines: lessons learned from experiences in Belgium, Denmark and the Netherlands. Journal of Pharmaceutical Health Services Research, 2017, Volume 8, Issue 3, September 2017, Pages 147-158

Vogler S, Schneider P.: Do pricing and usage-enhancing policies differ between biosimilars and generics? Findings from an international survey. Generics and Biosimilars Initiative Journal (GaBI Journal), 6(2): 79-88, 2017

Vogler S, Paris V, Ferrario A, Wirtz V, de Joncheere K, Schneider P.: How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Applied Health Economics and Health Policy, 15: 307-321, 2017

2016

Vogler S, Babar Z-U-D, Vitry A.: Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. The Lancet Oncology 17(1), No. 1: 39-47, 2016

Vogler S, Zimmermann N, Ferrario A, Wirtz V, de Joncheere K, Bak Pedersen H, Dedet G, Paris V, Mantel-Teeuwisse A, Babar Z-U-D and on behalf of the Scientific Programme Committee: Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. Journal of Pharmaceutical Policy and Practice, 9: 9, 2016

Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, De Joncheere K, Hill S. : Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med, 13: 5, 2016

Pani L, Montilla S, Németh G, Russo P, Viceconte G, Vogler S.: Balancing Access to Medicines and Sustainability in Europe: an Analysis from the Network of Competent Authorities on Pricing and Reimbursement (CAPR). Pharmacological Research, S1043-6618(16)30202-X, 2016

Vogler S, Habimana K, Zimmermann N.: Stakeholder preferences about policy objectives and measures of pharmaceutical pricing and reimbursement . Health Policy and Technology, 5; Issue 3: 213–225 , September 2016

Vogler S, Zimmermann N, de Joncheere K.: Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015. Health Policy, 120, Issue 12: 1363–1377, December 2016

Vogler S, Zimmermann N, Babar Z-U-D: Price comparison of high-cost originator medicines in European countries. Expert Review of Pharmacoeconomics & Outcomes 17 (2): 221-230

2015

Vogler S, Kilpatrick K, Babar Z-U-D.: Analysis of Medicine Prices in New Zealand and 16 European Countries. Value in Health 2015, 18(4), 2015

Vogler S, Österle A, Mayer S.: Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries. International Journal for Equity in Health, 14: 124, 2015

2014

Vogler S, Zimmermann N.: Aktivitäten von Krankenversicherungsträgern zur Etablierung eines rationalen Einsatzes von Arzneimitteln. Im Blickpunkt, 1/2014, 2014

Vogler S, Leopold C, Zimmermann N, Habl C, de Joncheere K.: The Pharmaceutical Pricing and Reimbursement Information (PPRI) initiative-Experiences from engaging with pharmaceutical policy makers. Health Policy and Technology 2014, 3: 139-148, 2014

Vogler S, Leopold C, Zuidberg C, Habl C.: Medicines discarded in household garbage: analysis of a pharmaceutical waste sample in Vienna. Journal of Pharmaceutical Policy and Practice 2014, 7(1): 6, 2014

Vogler S, Habimana K, Arts D.: Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries. Health Policy 2014, 117(3): 311-327, 2014

Leopold C, Mantel-Teeuwisse A.K, Vogler S, Valkova S, de Joncheere K, Leufkens H.G.M, Wagner A, Ross-Degnan D, Laing R.: Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. Bulletin of the World Health Organization 2014 , 92:630-640D

Leopold C, Zhang F, Mantel-Teeuwisse A.K., Vogler S, Valkova S, Ross-Degnan D, Wagner A.K.: Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses. International Journal for Equity in Health 2014 , 13:53

Babar Z-U-D, Gray A, Kiani A, Vogler S, Ballantyne P, Scahill S. : The future of medicines use and access research: using the Journal of Pharmaceutical Policy and Practice as a platform for change. Journal of Pharmaceutical Policy and Practice 2014, 7(1): 1-2, 2014

Vogler S, Zimmermann N, Mazag J.: Availability and procurement conditions of originator and generic medicines in hospitals – an exploratory study in five medium-sized European countries. Generics and Biosimilars Initiative Journal (GaBI Journal) 2014, 3(4): 168-75, 2014

2013

Vogler S, Zimmermann N, Leopold C, Habl C, Mazag J.: Discounts and Rebates Granted for Medicines for Hospital Use in Five European Countries. The Open Pharmacoeconomics & Health Economics Journal 2013, 5: 1-10, 2013

Vogler S, Zimmermann N, Habl C, Mazag J. : The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices. Cost Effectiveness and Resource Allocation 2013, 11: 15, 2013

Björkhem-Bergman L, Andersén-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, Malmström R, Vogler S, Godman B, Gustafsson LL.: Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. European Journal of Clinical Pharmacology 2013, 69(1): 73-8, 2013

Leopold C, Mantel-Teeuwisse A.K, Vogler S, de Joncheere K, Laing R.O, Leufkens H.G.M.: Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy 2013, 112: 209-16, 2013

Vogler S, Zimmermann N.: How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria. Generics and Biosimilars Initiative Journal (GaBI Journal) 2013, 2(2): 65-75, 2013

Leopold C, Vogler S, Piessnegger J, Bucsics A.: Aktuelle Heilmittelausgaben und arzneimittelpolitische Trends in Europa. Soziale Sicherheit 2013, 9: 414-429, 2013

Leopold C, Vogler S, Habl C, Mantel-Teeuwisse A.K, Espin J.: Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab. Health Policy 2013, 113(3): 313–22, 2013

Vogler S, Zimmermann N, Habl C.: Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries. Generics and Biosimilars Initiative Journal (GaBI Journal) 2013, 2(4): 178-87, 2013

2012

Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A.: Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review 2012, 5(1): 38-46, 2012

Vogler S.: The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries-an overview. Generics and Biosimilars Initiative Journal (GaBI Journal) 2012, 1(2): 93-100, 2012

Vogler S.: Preisbildung und Erstattung von Arzneimitteln in der EU - Gemeinsamkeiten, Unterschiede und Trends. [Title translated in English: Pricing and reimbursement of medicines in the EU], Pharmazeutische Medizin 2012, 14: 48-56, 2012

Leopold C, Vogler S, Mantel-Teeuwisse A, de Joncheere K, Leufkens H.G.M, Laing R.: Differences in external price referencing in Europe - A descriptive overview. Health Policy 2012, 104: 1, 2012

Vogler S.: How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries. Farmeconomia: Health economics and therapeutic pathways 2012, 13 (Suppl 3): 29-41, 2012

Vogler S, Zimmermann N.: The potential of generics policies: more room for exploitation. PPRI Conference Report. Generics and Biosimilars Initiative Journal (GaBI Journal) 2012, 1(3-4): 146-9, 2012

Leopold C, Mantel-Teeuwisse A.K, Seyfang L, Vogler S, de Joncheere K, Laing R.O, Leufkens H.G.M.: Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries. Southern Med Review 2012, 5(2): 34-41, 2012

2011

Vogler S, Habl C, Bogut M, Voncina L.: Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croatian Medical Journal (CMJ) 2011, 52: 183-97, 2011

Vogler S, Zimmermann N, Mazag J.: Procuring medicines in hospitals: results of the European PHIS survey. European Journal of Hospital Pharmacy Practice 2011, 17: 20-21, 2011

Editors of Medical Tribune.: Weltweit ähnliche Probleme: Arzneien & Sparzwang. [Title translated in English: Worldwide similar problems: Medicines & the need for cost-savings], 2011

Vogler S, Zimmermann N, Leopold C, de Joncheere K.: Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Review 2011, 4: 22-32, 2011

2010

Vogler S.: A European survey on medicines management in hospitals. European Journal of Hospital Pharmacy Practice 2010, 16: 12, 2010

2009

Vogler S, Espin J, Habl C.: Pharmaceutical Pricing and Reimbursement Information (PPRI) – new PPRI analysis including Spain. Pharmaceuticals Policy and Law 2009, 11: 213-34, 2009

2008

Vogler S.: Arzneimittelpreisbildung und Arzneimittelerstattung in der EU. [Title translated in English: Pharmaceutical pricing and reimbursement in the EU], Austrian Public Health Association Newsletter 2008, 4: 1-2, 2008

Leopold C, Vogler S, Habl C.: Was macht ein erfolgreiches Referenzpreissystem aus – Erfahrungen aus internationaler Sicht. [Title translated in English: Implementing a successful reference price system – Experiences from other countries], Soziale Sicherheit 2008, 11: 614-23, 2008

2006

Vogler S, Habl C, Leopold C.: Arzneimittel – wer zahlt? Erstattung und Selbstbeteiligung in der erweiterten EU. [Title translated in English: Pharmaceuticals: Who pays? Reimbursement and co-payments in the enlarged EU], Soziale Sicherheit 2006, 9: 411-8, 2006

Arts D, Habl C, Rosian I, Vogler S.: Pharmaceutical Pricing and Reimbursement Information (PPRI): a European Union project. Italian Journal of Public Health 2006, 3: 36-40, 2006

2003

Rosian I, Vogler S, Vander Stichele R, Larsen L, Odegaard B, Brahm A, et al.: EURO-MED-STAT–Monitoring expenditure and utilization of medicinal products in the European Union countries: a Public Health approach. European Journal of Public Health, 13 (3 Supplement): 95-100, 2003

2002

Rosian I, Vogler S.: Arzneimittelsysteme in Europa – ein vergleichender Überblick. [Title translated in English: Pharmaceutical systems in Europe – a comparative overview], Soziale Sicherheit 2002, 4: 165-74, 2002